You are here

  • Home
  • Archive
  • Volume 7, Issue 5
  • Review: β2 agonists are ineffective but increase adverse effects in acute bronchitis without underlying pulmonary disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: β2 agonists are ineffective but increase adverse effects in acute bronchitis without underlying pulmonary disease

https://doi.org/10.1136/ebm.7.5.146

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) J Fam Pract 50, 945; Smucny JJ, Flynn CA, Becker LA, et al.. Are β2-agonists effective treatment for acute bronchitis or acute cough in patients without underlying pulmonary disease? A systematic review.. Nov;. :. –51.
    OpenUrlPubMedWeb of Science

    
 
 QUESTION: In patients who have acute bronchitis without underlying pulmonary disease, are β2 agonists more effective than placebo or alternative treatments for improving symptoms?

    Data sources

    Studies were identified by searching Medline (1966 to 2000), EMBASE/Excerpta Medica (1974 to 2000), the Cochrane Library (August 2000), conference proceedings, the System for Information on Grey Literature in Europe (1980 to 2000), and Science Citation Index (1990 to 2000). Bibliographies of relevant articles were reviewed, and US manufacturers of brand-name β2 agonists were contacted for unpublished studies.

    Study selection

    Studies in any language were selected if they were randomised controlled trials (RCTs) comparing β2 agonists with placebo or an alternative treatment in patients ≥ 2 years of age who had acute bronchitis or acute cough without a clear cause (eg, pneumonia, pertussis, or sinusitis).

    Data extraction

    Data were extracted on sample size, patient inclusion and …

    View Full Text